Novo Nordisk Shares Plunge as Heart Drug Trial Fails to Meet Key Goal

Novo Nordisk faced a sharp selloff on Friday after the Danish pharmaceutical giant announced that its experimental heart drug ziltivekimab failed to achieve its primary goal in a late-stage clinical trial. The drugmaker reported that the medicine did not produce a statistically meaningful reduction in major adverse cardiovascular events compared to a placebo, dealing a blow to investor confidence in the company’s pipeline.

The Copenhagen-listed shares were last seen down 7.4%, while American depositary receipts dropped 8.6% in premarket trading. If these losses hold through the session, shares will turn negative for the year and mark the worst single-day performance since February, when the company released disappointing results from a head-to-head trial of its next-generation weight-loss drug CagriSema versus rival medicine from Eli Lilly.

The trial tested whether ziltivekimab, which blocks the inflammatory IL-6 pathway, could reduce the risk of a first major cardiovascular event when added to standard treatment. While the experimental medicine showed some biological effect, this did not translate into meaningful clinical benefits for patients with certain diseases, Novo Nordisk said in a statement.

Trial Details and Patient Population

The Phase 3 study enrolled more than 6,300 people who had atherosclerotic cardiovascular disease, chronic kidney disease and elevated inflammation. Researchers measured major adverse cardiovascular events, or MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke. Despite demonstrating target engagement and inhibition of the IL-6 pathway through expected reductions in free IL-6 and high-sensitivity C-reactive protein, ziltivekimab failed to deliver the hoped-for reduction in MACE risk.

Overall adverse-event rates in the trial were similar between the treatment and placebo groups, although serious infections occurred more frequently among patients receiving ziltivekimab. The study found no difference in overall mortality between the two groups, suggesting the drug’s inflammatory pathway blockade did not translate into survival benefits.

“While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease,” chief scientific officer Martin Holst Lange said.

Broader Clinical Program Continues

Novo Nordisk gained control of ziltivekimab through a 2020 acquisition of Corvidia Therapeutics, for which it paid $725 million. The drug is part of a sprawling clinical program involving three late-stage trials that have collectively enrolled more than 20,000 people. Two additional studies in people with heart failure or who have experienced an acute heart attack remain ongoing, with results expected next year.

These trials all aim to show that lowering levels of an inflammatory protein called IL-6 can reduce the risk of heart-related complications and death. The failure of the first Phase 3 trial casts doubt on this approach to treating cardiovascular disease and raises questions about the likelihood of success in the remaining studies.

The company stated that although the disappointing outcome will not impact its 2026 adjusted operating profit outlook, it will result in a non-cash impairment charge in the third quarter. Novo Nordisk, known for its blockbuster weight-loss drugs Ozempic and Wegovy, must now reassess the commercial potential of its cardiovascular pipeline.

Analyst Reactions and Strategic Implications

Analysts from Jefferies and Citi both characterized the market reaction as potentially disproportionate given ziltivekimab’s relatively small contribution to Novo‘s overall portfolio. However, Jefferies noted the strategic significance of the setback, explaining that it removes one of the company’s more credible non-obesity growth opportunities.

“The result is strategically negative as it removes one of Novo’s more credible non-obesity growth opportunities and again reinforces the company’s reliance on commercial execution in obesity and sourcing external innovation for driving growth,” Jefferies said.

The missed endpoint represents the latest blow to the Danish drugmaker, which has been racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S. market. The company’s heavy dependence on its obesity franchise creates pressure to demonstrate success in other therapeutic areas.

Recent Performance and Market Context

Friday’s setback came amid cautious investor optimism around Novo Nordisk, driven mainly by the successful launch of the Wegovy pill, the first oral GLP-1 for weight loss, in the United States in January. The company’s U.S.-listed shares had entered Friday up just 1% for the year, a modest gain that now appears likely to evaporate.

Eli Lilly launched a competing pill, Foundayo, in April, which has experienced slower uptake in the market. The competitive dynamics in the weight-loss drug space remain intense, with both pharmaceutical giants vying for dominance in what analysts project will become a multibillion-dollar market over the coming years.

The failure of ziltivekimab also hurt the stocks of multiple other biotechnology companies developing different cardiovascular drugs that similarly target inflammation, suggesting broader investor skepticism about this therapeutic approach. The setback raises fundamental questions about whether modulating inflammatory pathways can deliver meaningful cardiovascular benefits in clinical practice.

Looking Forward

Novo Nordisk maintains its strategic commitment to cardiovascular disease despite the disappointing trial results. The company continues to invest in research and development across multiple therapeutic areas, seeking to diversify beyond its obesity and diabetes franchises. However, the ziltivekimab failure underscores the inherent risks and challenges of pharmaceutical development, where promising biological mechanisms do not always translate into clinical success.

Investors and analysts will now watch closely for results from the two remaining late-stage trials of ziltivekimab, which could either validate the IL-6 targeting approach in different patient populations or confirm that this strategy lacks clinical utility. The outcomes of these studies, expected next year, will prove critical for Novo Nordisk‘s cardiovascular pipeline and its broader efforts to demonstrate innovation beyond weight-loss treatments.